Skip to content

Addiction

ISSN 0965-2140, 1360-0443

102 papers in the library · 4,149 citations · publishing 1993-2026

Papers

Sort Most recent Most cited

When psychedelic discourse meets local narrative: Selective uptake of psychedelic meanings surrounding mad honey in Nepal

Addiction September 29, 2026 Sharon R. Sznitman, Surendra Tiwari

Abstract: Aims: ‘Mad honey’ is produced when bees collect nectar from Rhododendron species containing grayanotoxins, naturally occurring diterpenoid toxins that can produce dose‐dependent intoxication. It has long been embedded in Nepalese medicinal and ritual practices but has recently become part of global psychedelic discourse. This study examined how globally circulating discourse and local...

Psychological change processes in alcohol use disorder: A qualitative study of 5‐methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) with cognitive behavioural therapy

Addiction August 3, 2026 Mathieu Seynaeve, Fiona Dunbar, Anna O. Ermakova et al.

BACKGROUND AND AIMS: This study qualitatively explored psychological change processes as described by participants and therapists within a phase 2a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a single dose of intranasal 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT; BPL-003) administered alongside psychological support and manualised cognitive behavioural...

Trends in new psychoactive substance poisonings in the Netherlands: A 14-year retrospective analysis (2012-2025).

Addiction July 7, 2026 Johanna J Nugteren-Van Lonkhuyzen, Irma S Van den Hengel-Koot, Claudine C Hunault et al.

Data on the presence of new psychoactive substances (NPS) mainly originate from drug-checking, law enforcement and wastewater analysis sources, while data on NPS poisonings are scarce. In Europe, the documented incidence rate of NPS poisonings is highest in the Netherlands. We investigated temporal trends in NPS poisonings reported to the Dutch Poisons Information Center (DPIC) between 2012 and...

DOI: 10.1111/add.70511 (opens in new tab) Full text (opens in new tab) Cathinones Designer benzodiazepines Designer drugs Phenethylamines +2

Cannabis use, affect and emotion regulation in daily life: A 3-week experience sampling method study in people who smoke cannabis almost daily.

Addiction July 7, 2026 A. P. G. Donate, Janna Cousijn, Emese Kroon et al.

BACKGROUND AND AIMS Although many people who use cannabis report mood-enhancing effects, affective responses are thought to vary within and between individuals. This study examined the bidirectional associations between momentary affect and cannabis use and the potential moderating role of emotion regulation in this. DESIGN Intensive longitudinal observational study using experience sampling...

Changes over time in hallucinogen-related emergency department visits in Ontario, Canada.

Addiction July 1, 2026 Daniel T. Myran, Rachael MacDonald-Spracklin, Alexander R Levesque et al.

Recent increasing interest in hallucinogens has underscored the critical gaps in our understanding of their adverse health effects and healthcare usage over time. The current study aimed to examine changes in emergency department (ED) visit rates involving hallucinogens, clinical outcomes of visits and the characteristics of individuals with ED visits involving hallucinogens. Repeated...

DOI: 10.1111/add.70363 (opens in new tab) Full text (opens in new tab) Clinical outcomes Co‐morbid mental health Emergency department visits Hallucinogens +4

The feasibility of mindfulness-based relapse prevention for adults with substance use disorders (illicit drugs) in a Chinese population: A pilot randomized controlled trial.

Addiction April 30, 2026 Ka Tsun Ting, Ivan Chun Him Leung, Dicken Cheong-Chun Chan et al.

Background and aims: Mindfulness-based relapse prevention (MBRP) has been shown to be beneficial to individuals with substance use disorder (SUD) in the West. The current pilot study aimed at testing the feasibility of MBRP in a Chinese population. Design: This pilot study adopted a design of randomized controlled trial comparing MBRP with treatment-as-usual group (TAU). Setting: Participants...

DOI: 10.1111/add.70441 (opens in new tab) Substance use disorder Humans Substance-related disorders Feasibility studies +11

Unlocking 'stuckness' and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic-assisted therapy for substance use and mental health problems.

Addiction March 30, 2026 Sarah J Catchlove, Katrin Oliver, Michael Savic et al.

Australia recently down-scheduled and authorised psychedelic-assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness. While service leaders and clinicians are crucial to implementation, little research examines their...

DOI: 10.1111/add.70403 (opens in new tab) Full text (opens in new tab) Alcohol use disorders Health service design Implementation Integrated care +3

Measuring the psychoactive effects of ketamine in alcohol use disorder: When assessment shapes experience

Addiction March 11, 2026 Christina Mcanulty, Nicolas Garel

Bloy et al. [1] provide an important and methodologically rigorous secondary analysis of the Ketamine for the reduction of Alcoholic Relapse (KARE) trial, examining whether acute psychoactive effects mediate the therapeutic impact of ketamine in alcohol use disorder (AUD). Their finding that dissociative and perceptual effects did not mediate abstinence outcomes is clinically relevant, and...

DOI: 10.1111/add.70396 (opens in new tab) Ketamine Alcohol Psychoactive drug Medline +1

Psilocybin microdosing in the United States: Insights from a nationally representative survey

Addiction March 8, 2026 Michelle Priest, Beau Kilmer, Rajeev Ramchand et al. 1 citation

At least 8.4 million US adults have microdosed psilocybin in their lifetime. Those who have used psilocybin within the past year are more likely to report microdosing the last time they used than those who have used psilocybin more than one year ago; however, approximately 15% respondents who used psilocybin in their lifetime were unsure whether they microdosed the last time they used....

DOI: 10.1111/add.70368 (opens in new tab) Psilocybin Multinomial logistic regression Epidemiology Microdose +6

Cannabis vaping and mental health: The association of Δ-9-tetrahydrocannabinol and cannabidiol with anxiety and depressive symptoms-Findings from the United States National Youth Tobacco Survey (2021-2023).

Addiction March 2026 Jack Chung, Daniel Stjepanović, Brandon Cheng et al.

Cannabis use is associated with psychiatric comorbidities, and the use of elta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) produces different neurophysiological and pharmacological effects. This study estimated the strength of associations between vaping of THC and CBD with depressive and anxiety symptoms in adolescents. Observational data were drawn from three years of the nationally...

The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial

Addiction February 16, 2026 Cassie Bloy, Ananya Sarma, Bethan Marsh et al. 1 citation

People with alcohol use disorder experience alterations in consciousness from 0.8 mg/kg intravenous ketamine administration. Ketamine's effects appear to be broadly consistent across three repeated infusions. Ketamine-related reductions in alcohol consumption do not appear to be mediated by the acute psychoactive effects of ketamine.

Hippocampal subfield differences in people with and without recreational ketamine use: Insights from multi-modal neuroimaging.

Addiction January 29, 2026 Yi-Hsuan Liu, Chia-Chun Hung, Marc N Potenza et al.

Recreational ketamine use has increased globally and is associated with psychiatric and cognitive concerns. The hippocampus in preclinical models shows damage and working-memory disruption with repeated dosing. However, whether specific hippocampal subregions may differ in people with chronic ketamine use remains unclear. In Taiwan, ketamine is predominantly consumed by smoking ketamine mixed...

DOI: 10.1111/add.70331 (opens in new tab) Full text (opens in new tab) Ketamine N‐methyl‐d‐aspartate receptors Functional neuroimaging Hippocampus +4

Rare but relevant: Ibogaine and cardiovascular complications-prolonged QT interval and ventricular arrhythmias.

Addiction January 20, 2026 Tibor Markus Brunt 2 citations

Revived interest in psychedelic-assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti-addictive potential. Evidence from observational, open-label, and limited randomized placebo-controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in opioid and cocaine-dependent individuals, primarily...

DOI: 10.1111/add.70319 (opens in new tab) Full text (opens in new tab) Noribogaine Qt interval Addiction treatment Cardiovascular +1

A qualitative analysis of participant expectations and experiences of psilocybin‐assisted psychotherapy for methamphetamine use disorder

Addiction December 22, 2025 Jonathan Brett, Toby Lea, Elizabeth Knock et al.

Abstract Background and aims There is an urgent unmet need for novel treatments for methamphetamine (MA) use disorder. We explored the qualitative experiences of people participating in a study of psilocybin‐assisted psychotherapy (PAT) to treat MA use disorder. Design and setting Qualitative study of participants enrolled in a single arm, open‐label pilot study of PAT for MA use disorder...

DOI: 10.1111/add.70284 (opens in new tab) Qualitative research Qualitative analysis Interpersonal communication Focus group +7

5‐Methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction December 10, 2025 John Marsden, Michael Kelleher, Fiona Dunbar et al. 2 citations

Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive Behavioural Therapy (CBT). Design Open‐label,...

DOI: 10.1111/add.70260 (opens in new tab) Alcohol use disorder Tolerability Craving Clinical trial +4

Rare but relevant: MDMA and hyponatraemia

Addiction December 8, 2025 María Rita Concepción García, Nelson G. M. Gomes, Diana Dias Da Silva

Conventionally used for its stimulant, empathogenic and entactogenic effects, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is one of the most commonly used psychoactive drugs, specifically among young adults and in nightlife and recreational party contexts. Often perceived as a safe drug, MDMA can display an array of toxic effects on multiple organs, with hyponatraemia (a low blood sodium...

DOI: 10.1111/add.70255 (opens in new tab) MDMA Ecstasy Hyponatremia Electrolyte disorder +10

The relationship between 3,4-methylenedioxymethamphetamine (MDMA) use in young adulthood and anxiety or depressive disorders in the mid-30s: Findings from the Victorian Adolescent Health Cohort Study.

Addiction December 1, 2025 Zachary Bryant, Kirsten Morley, Jessica A Kerr et al.

MDMA (3,4-methylenedioxymethamphetamine or "Ecstasy") is the fourth-most used illicit substance globally. While previous research found links between MDMA use and mental health outcomes, the direction and nature of this relationship remain unclear. This study assessed whether MDMA use in early adulthood increases the risk of anxiety or depression in mid-30s. A longitudinal, population-based...

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction September 20, 2025 Elizabeth Knock, Krista J. Siefried, Gillinder Bedi et al. 4 citations

Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study. Setting Outpatient public stimulant treatment program at St. Vincent's Hospital, Sydney,...

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction July 24, 2025 Amandine Luquiens, Dahbia Belahda, Carine Graux et al. 22 citations

Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted psychotherapy for patients with comorbid...

DOI: 10.1111/add.70152 (opens in new tab) Alcohol use disorder Dual disorders Feasibility Psychedelics +14

The landscape of ketamine use disorder: Patient experiences and perspectives on current treatment options.

Addiction April 28, 2025 Rebecca Harding, Tamsin Barton, Maeve Niepceron et al. 14 citations

To report the symptoms and aetiology of ketamine use disorder (KUD), gauge the effectiveness of current treatment services and identify strategies to enhance patient access and outcomes. Mixed-methods, cross-sectional questionnaire. Electronic survey from November 2023 to April 2024. Participants were recruited through snowball sampling, social media and referrals from UK addiction treatment...

DOI: 10.1111/add.70073 (opens in new tab) Full text (opens in new tab) Non‐treatment‐seeking abstinence Ketamine addiction Substance abuse treatment Global drug dependence +2

Tusi use among the New York City nightclub-attending population.

Addiction April 20, 2025 Joseph J Palamar, Nina Abukahok, Patricia Acosta et al. 7 citations

'Tusi', also known as 'tusibí' or 'pink cocaine', is a drug concoction which previously emerged in Latin America and Europe and has recently acquired popularity in the United States (US). Consumers are often unaware that Tusi contains a mixture of ketamine and other drugs, and the concoction can be confused with 2C/2C-B (ring-substituted phenethylamines/4-bromo-2,5-dimethoxyphenethylamine) or...

Rare but relevant: Ketamine-induced cystitis - an in-depth review for addiction medicine.

Addiction April 4, 2025 Asem Abdelrahman, Mo Belal 4 citations

Ketamine-induced cystitis is an increasingly recognized complication associated with the addictive use of ketamine, a dissociative anesthetic. This article provides a comprehensive overview, focusing on its pathophysiology, clinical presentation, diagnosis, management strategies, and implications for addiction treatment. The British Association of Urological Surgeons consensus serves as a...

DOI: 10.1111/add.70052 (opens in new tab) Full text (opens in new tab) Ketamine bladder dysfunction Ketamine cystitis Ketamine uropathy Ureteric stricture +6

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction January 30, 2025 Theodore Piper, Francesca Small, Michael Kelleher et al. 27 citations

Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its quality; and to offer recommendations for...

Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities.

Addiction January 16, 2025 Noa Krawczyk, Megan Miller, Emma Yuanqi Gu et al. 2 citations

The opioid crisis continues to exert a tremendous toll in North America, with existing interventions often falling short of addressing ongoing needs. Psychedelics are emerging as a possible alternative therapy for mental health and substance use disorders. This study aimed to gather insights on how people use or are considering using psychedelics to manage opioid use disorder (OUD), how these...

Comparison of strength and adulteration between illicit drugs obtained from cryptomarkets versus off-line.

Addiction 2025 Leigh Coney, Amy Peacock, Daan van der Gouwe et al. 8 citations

Drugs sold on cryptomarkets are thought to have lower levels of adulteration and higher strength compared with those sourced off-line. The present study aimed to determine whether cryptomarket and off-line-sourced 3,4-methylenedioxy-N-methamphetamine (MDMA), cocaine, amphetamine, methamphetamine and lysergic acid diethylamide (LSD) differed in adulteration and strength. A between-groups design...

DOI: 10.1111/add.16665 (opens in new tab) Full text (opens in new tab) Adulteration Illicit drugs Drug checking Drug quality +8